New uses and formulations of glucagon for hypoglycaemia
| Autor: | Francisco Javier Arroyo-Díez, Pilar Isabel Beato-Víbora |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
endocrine system type 1 diabetes medicine.medical_treatment 030209 endocrinology & metabolism mini-dose glucagon Review Glucagon 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine 030212 general & internal medicine Pharmacology Type 1 diabetes exercise business.industry Insulin digestive oral and skin physiology lcsh:RM1-950 General Medicine dual-hormone artificial pancreas medicine.disease Endocrinology nasal glucagon lcsh:Therapeutics. Pharmacology glucagon Molecular Medicine business Complication injectable glucagon hormones hormone substitutes and hormone antagonists hypoglycaemia |
| Zdroj: | Drugs in Context, Vol 8, Pp 1-10 (2019) Drugs in Context |
| ISSN: | 1740-4398 |
| Popis: | Hypoglycaemia is the more frequent complication of insulin therapy and the main barrier to tight glycaemic control. Injectable glucagon and oral intake of carbohydrates are the recommended treatments for severe and non-severe hypoglycaemia episodes, respectively. Nasal glucagon is currently being developed as a ready-to-use device, to simplify severe hypoglycaemia rescue. Stable forms of liquid glucagon could open the field for different approaches for mild to moderate hypoglycaemia treatment, such as mini-doses of glucagon or continuous subcutaneous glucagon infusion as a part of dual-hormone closed-loop systems. Pharmaceutical companies are developing stable forms of native glucagon or glucagon analogues for that purpose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|